A DPP-4 inhibitor (a 'gliptin')
Linagliptin
A once-daily tablet for type 2 diabetes that gently lowers blood sugar with a low risk of hypos and little effect on weight.
What is Linagliptin?
Linagliptin is a DPP-4 inhibitor (a 'gliptin') used to help control blood sugar in type 2 diabetes. It is taken as a once-daily tablet, is generally weight-neutral, and on its own carries a low risk of hypos. It is often added when metformin alone is not enough, or used when metformin is not suitable.
Education and reference only. This is a plain-language guide to Linagliptin — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Linagliptin is an oral medicine for type 2 diabetes, taken as a once-a-day tablet. It is one of the gliptins (DPP-4 inhibitors) and is often added to metformin, or used in people who cannot take metformin. A practical advantage is that, unlike many other diabetes tablets, it does not normally need a dose change in people with reduced kidney function, which makes it a useful option for older people and those with kidney problems.
How it works
After eating, the gut releases hormones called incretins (such as GLP-1) that prompt the pancreas to release insulin and reduce the amount of glucose the liver makes. These hormones are quickly broken down by an enzyme called DPP-4. Linagliptin blocks DPP-4, so the body's own incretin hormones last longer and work mainly when blood sugar is rising after a meal. Because this effect is glucose-dependent, it rarely pushes blood sugar too low on its own.
Company & origin
Originated / developed by: Boehringer Ingelheim.
Developed by Boehringer Ingelheim and first approved around 2011 (United States and Europe).
What it treats
Conditions Linagliptin is used for
Practical use
How to take Linagliptin
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- Take it once a day, at about the same time each day; it can be taken with or without food.
- If you miss a dose, take it when you remember unless it is nearly time for the next one — never take two doses together.
- On its own it rarely causes hypos, but the risk rises if combined with a sulfonylurea or insulin, so your team may adjust those.
- Keep taking it even when you feel well — it works quietly in the background to keep blood sugar steady.
- Tell a doctor straight away if you get severe, ongoing tummy pain (rarely it can be linked to pancreatitis).
Weighing it up
Advantages & disadvantages of Linagliptin
Advantages
- Simple once-daily tablet that is generally weight-neutral.
- Low risk of hypos when used on its own.
- Usually no dose change needed in kidney impairment, unlike many alternatives.
- Well tolerated by most people, including many older adults.
Disadvantages
- Lowers blood sugar less powerfully than some other options.
- Does not help with weight loss or directly protect the heart, unlike SGLT2 inhibitors or GLP-1 medicines.
- Rarely linked to pancreatitis and to joint pain.
Practical use
Good to know
Linagliptin is taken once a day and is usually well tolerated, with little effect on weight and a low risk of hypos when used by itself. It is mainly removed from the body through the gut rather than the kidneys, so it is often chosen when kidney function is reduced. It is taken long-term alongside diet, activity and any other diabetes medicines your team has prescribed.
Who should not take it / use with caution
- People who have had a serious allergic reaction to linagliptin or another gliptin.
- Use with caution, and report symptoms, in anyone with a history of pancreatitis.
- Not used in type 1 diabetes or for diabetic ketoacidosis.
Monitoring
- Routine diabetes checks of blood sugar control (including HbA1c).
- Review of overall diabetes treatment and other risk factors.
- Prompt review if pancreatitis or severe joint pain is suspected.
Side effects
- Often none. Possible effects include a stuffy or runny nose and cough.
- Joint pain (which can be severe) — report it, as it usually settles after stopping.
- Rarely, inflammation of the pancreas (pancreatitis) — seek urgent help for severe, persistent tummy pain.
- Rarely, blistering skin reactions (bullous pemphigoid).
Key interactions
- Hypo risk increases when combined with a sulfonylurea or insulin.
- Certain medicines (such as rifampicin) can reduce how well linagliptin works.
- Tell your team about all your medicines so the combination can be reviewed.
Available as: Oral tablets.
Answers
Linagliptin: frequently asked questions
Will linagliptin cause hypos?
On its own it rarely causes low blood sugar, because it mainly works when blood sugar is rising after meals. The risk goes up if it is combined with a sulfonylurea or insulin, so your team may adjust those medicines.
Does linagliptin affect my weight?
It is generally weight-neutral, meaning most people neither gain nor lose much weight on it. If weight loss is a priority, other diabetes medicines such as GLP-1 agonists or SGLT2 inhibitors may be considered.
Can I take it if I have kidney problems?
Usually yes. Linagliptin is mostly removed through the gut rather than the kidneys, so it generally does not need a dose change in kidney impairment — which is one reason it is chosen for older people.
Do I take it with food?
It can be taken with or without food, once a day at about the same time. Take it consistently to keep your blood sugar steady.
When should I seek urgent help?
Seek urgent medical help for severe, persistent tummy pain that may spread to your back, as this can rarely be a sign of pancreatitis. Also report severe joint pain or any blistering skin reaction.
The wider class
About DPP-4 inhibitors
Linagliptin belongs to the dpp-4 inhibitors class. For how the class as a whole works, its shared safety principles and monitoring, see the full guide.
Browse by body system
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.